Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been given a consensus recommendation of “Moderate Buy” by the fifteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $56.36.

KYMR has been the topic of a number of analyst reports. HC Wainwright lifted their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a report on Friday, February 28th. BMO Capital Markets initiated coverage on Kymera Therapeutics in a report on Friday, December 6th. They set a “market perform” rating and a $55.00 price objective on the stock. Citigroup initiated coverage on Kymera Therapeutics in a report on Thursday, March 13th. They issued a “buy” rating and a $52.00 target price for the company. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $38.00 to $57.00 in a research note on Monday, December 2nd. Finally, Leerink Partners reiterated an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a report on Friday, December 27th.

Insider Transactions at Kymera Therapeutics

In related news, COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the sale, the chief operating officer now directly owns 67,800 shares of the company’s stock, valued at approximately $2,064,510. This represents a 2.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Bruce N. Jacobs sold 7,035 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the transaction, the chief financial officer now directly owns 201,886 shares in the company, valued at $6,147,428.70. The trade was a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 13,788 shares of company stock valued at $455,202 in the last three months. 15.82% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its holdings in Kymera Therapeutics by 14.9% in the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock worth $213,514,000 after purchasing an additional 688,967 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in shares of Kymera Therapeutics by 14.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock worth $207,184,000 after buying an additional 650,000 shares during the last quarter. Deerfield Management Company L.P. Series C bought a new stake in shares of Kymera Therapeutics during the 4th quarter worth about $23,856,000. Boxer Capital Management LLC bought a new stake in shares of Kymera Therapeutics during the 4th quarter worth about $17,098,000. Finally, Jennison Associates LLC increased its holdings in shares of Kymera Therapeutics by 85.8% during the 3rd quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock valued at $37,754,000 after acquiring an additional 368,394 shares during the last quarter.

Kymera Therapeutics Trading Down 1.3 %

Shares of NASDAQ KYMR opened at $34.03 on Friday. The stock has a market cap of $2.21 billion, a P/E ratio of -14.54 and a beta of 2.22. Kymera Therapeutics has a twelve month low of $29.07 and a twelve month high of $53.27. The stock has a 50 day moving average of $37.18 and a two-hundred day moving average of $42.56.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The business had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. As a group, research analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.